Sridhar Narayan
Vice President, Medicinal Chemistry ReviR Therapeutics
Sridhar Narayan, PhD, MBA, is Vice President, Medicinal Chemistry at ReviR Therapeutics, where he leads the development of novel drugs that modulate RNA targets and applies AI/ML approaches to drug discovery. A scientist, entrepreneur, and seasoned pharma leader, he brings deep experience spanning oncology, immunology and inflammation, metabolic disorders, infectious diseases, CNS, and rare disease. Prior to ReviR, Sridhar held leadership roles at Satellos Bioscience, Appili Therapeutics, Navitor Pharmaceuticals, AstraZeneca, and Eisai, helping advance projects from early discovery into first-in-human studies. He has also advised biotech and venture firms on drug discovery, development strategy, business development, and new venture creation.
Seminars
- Overcoming challenges while progressing oral RNA splicing modulators into the clinic
- Optimizing activity and selectivity on multiple targets to achieve the best target profile
- Sharing progress on RTX-317 as ReviR advances its next RNA splicing modulator program toward IND-enabling studies
